Advances in the design and delivery of RNA vaccines for infectious diseases

IF 15.2 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Abhijeet Girish Lokras , Thomas Rønnemoes Bobak , Saahil Sandeep Baghel , Federica Sebastiani , Camilla Foged
{"title":"Advances in the design and delivery of RNA vaccines for infectious diseases","authors":"Abhijeet Girish Lokras ,&nbsp;Thomas Rønnemoes Bobak ,&nbsp;Saahil Sandeep Baghel ,&nbsp;Federica Sebastiani ,&nbsp;Camilla Foged","doi":"10.1016/j.addr.2024.115419","DOIUrl":null,"url":null,"abstract":"<div><p>RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of global significance, <em>e.g.</em>, infectious diseases. The highly successful messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed at record speed during the coronavirus disease 2019 pandemic. A consequence of this is exceptionally shortened vaccine development times, which in combination with adaptability makes the RNA vaccine technology highly attractive against infectious diseases and for pandemic preparedness. Here, we review state of the art in the design and delivery of RNA vaccines for infectious diseases based on different RNA modalities, including linear mRNA, self-amplifying RNA, <em>trans</em>-amplifying RNA, and circular RNA. We provide an overview of the clinical pipeline of RNA vaccines for infectious diseases, and present analytical procedures, which are paramount for characterizing quality attributes and guaranteeing their quality, and we discuss future perspectives for using RNA vaccines to combat pathogens beyond SARS-CoV-2.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"213 ","pages":"Article 115419"},"PeriodicalIF":15.2000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24002412/pdfft?md5=d95ea72925743ff2f59eadf7fc5ec9a0&pid=1-s2.0-S0169409X24002412-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced drug delivery reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169409X24002412","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of global significance, e.g., infectious diseases. The highly successful messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed at record speed during the coronavirus disease 2019 pandemic. A consequence of this is exceptionally shortened vaccine development times, which in combination with adaptability makes the RNA vaccine technology highly attractive against infectious diseases and for pandemic preparedness. Here, we review state of the art in the design and delivery of RNA vaccines for infectious diseases based on different RNA modalities, including linear mRNA, self-amplifying RNA, trans-amplifying RNA, and circular RNA. We provide an overview of the clinical pipeline of RNA vaccines for infectious diseases, and present analytical procedures, which are paramount for characterizing quality attributes and guaranteeing their quality, and we discuss future perspectives for using RNA vaccines to combat pathogens beyond SARS-CoV-2.

Abstract Image

设计和提供治疗传染病的 RNA 疫苗的进展。
RNA 药物代表了全球重大疾病(如传染病)治疗和预防的范式转变。在 2019 年冠状病毒疾病大流行期间,针对严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的信使核糖核酸(mRNA)疫苗以创纪录的速度研制成功。其结果是疫苗开发时间大大缩短,再加上适应性强,使得 RNA 疫苗技术在预防传染病和大流行病方面具有很强的吸引力。在此,我们回顾了基于不同 RNA 模式(包括线性 mRNA、自扩增 RNA、反式扩增 RNA 和环状 RNA)的 RNA 疫苗设计和递送技术的最新进展。我们概述了用于传染病的 RNA 疫苗的临床应用,介绍了对表征质量属性和保证质量至关重要的分析程序,并讨论了使用 RNA 疫苗抗击 SARS-CoV-2 以外病原体的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
28.10
自引率
5.00%
发文量
294
审稿时长
15.1 weeks
期刊介绍: The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery. In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信